In the published article titled “Publication: Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer” JTO Clin Res Rep. 2023;4:100452:
A typo has come to our attention. When discussing AUC increase of capmatinib when co-administered with itraconazole, the paper incorrectly cites the AUC increase as 421%. It should be corrected to 42% in coordination with reference 16.
Listed below are where the corrections should be made:
Page 6: In the MET Inhibitors section
-
•
“Coadministration of itraconazole increased the AUC of capmatinib by 421%”
Page 7:
-
•
Table 2
Page 11: Discussion Section, please change the sentence in bullet point 1 to the sentence in bullet point 2 to keep the same contextual integrity of highlighting the degree of concentration changes by CYP inhibition.
-
•
Please change “For instance, coadministration of capmatinib and itraconazole (a strong CYP 3A4 inhibitor) can result in a 421% increase in AUC, whereas coadministration of osimertinib and itraconazole only resulted in a 24% increase in AUC”
-
•
To “For instance, coadministration of neratinib and itraconazole (a strong CYP 3A4 inhibitor) can result in a 481% increase in AUC, whereas coadministration of osimertinib and itraconazole only resulted in a 24% increase in AUC”